FAST NEWS: Brii Bioscience shares rise on favorable hepatitis B data
The latest: Brii Biosciences Ltd. (2137.HK) said Wednesday that a study for its BRII-179 product to treat hepatitis B has shown favorable results in inducing functional immune responses. Looking up: The company…
Recent Articles
RELATED ARTICLES
-
As Covid drug cash dwindles, Vigonvita targets new remedies
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
